Symbiosis Pharmaceutical Services, an injectable manufacturer based in Stirling, UK, plans to expand its sterile filling facility following increased demand for its services from both the U.S. and Europe.
 
Symbiosis will expand its Scotland site by 20%, adding a new controlled temperature storage area and additional room for its growing quality and project management teams.
 
The expansion comes a year after the company was granted a commercial manufacturer’s / importers license by the Medicines and Healthcare Regulatory Agency (MHRA) for the GMP-manufacture of aseptically-filled licensed commercial products. 
 
Its core business remains the sterile fill/finish of biologic and small molecule products into vials for clinical trials but the CMO has branched into providing a solution for increasing numbers of small scale commercial manufacturing projects.
 
Colin MacKay, chief executive officer of Symbiosis Pharmaceutical Services, said, “The decision to expand our facility comes both as a result of growing client demand for our small-scale sterile manufacturing services and also in line with the latest guidelines from the MHRA. As we scale-up and regularly manufacture both commercial and clinical drug products, it’s essential for us to plan ahead with regards to product segregation and storage to ensure we continue to meet regulatory compliance guidelines demanded by the MHRA both now and in the future.It’s important we accurately forecast to ensure we have the capacity to meet customers’ needs and to underpin the strong relationships we have built with our clients.”